Treatment News : Early Treatment Lowers HIV’s Spread and Benefits Economy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 2, 2014

Early Treatment Lowers HIV’s Spread and Benefits Economy

Widespread early treatment of HIV has expanded life expectancies, prevented massive numbers of new HIV cases and saved billions of dollars in skirted life expectancy losses. Two new papers address the manifold benefits of early antiretroviral (ARV) treatment in the March issue of Health Affairs, which features various papers about HIV.

One study, out of the University of Southern California (USC), found that, between 1996 and 2009, early treatment of HIV prevented 188,700 new cases of the virus in the United States (by suppressing viral load, making those taking ARVs vastly less likely to pass on HIV) and sidestepped $128 billion in life expectancy losses. Those who started treatment with a CD4 count greater than 500 accounted for 80 percent of the prevented cases of HIV.

Another USC study found that those who started ARVs with CD4s between 350 and 500 gained an average of 6.1 years of life expectancy, while those who started treatment with greater than 500 CD4 cells gained 9 years of life expectancy. Valuing each life year at $150,000, the investigators calculated that early treatment yielded an economic benefit of $80 billion between 1996 and 2009.

The second study found that those who start treatment later have a much higher risk of dying. Compared with those who begin ARVs with between 350 and 500 CD4s, the late starters had a 28 percent higher mortality risk. Compared with those who begin treatment with greater than 500 CD4s, those who start late have a 116 percent greater risk of dying.  

Those who started treatment the earliest could expect 40 subsequent years of life.

Yet another USC study projected that by 2017 an additional 466,153 people will be tested for HIV because of the ACA, and that 2,598 new cases will be identified. The ACA is likely to shave down the number of people who are unaware of their HIV infection by 22 percent. If all states were to expand their Medicaid programs, this effect could grow by 30 percent.

To read the abstract of the study concerning prevented cases of HIV, click here.

To read the abstract of the life expectancy study, click here.

To read the abstract of the study about the effects of the ACA, click here.

To access various other Health Affairs abstracts about HIV, click here.

Search: HIV, early treatment, Health Affairs, Obamacare, Affordable Care Act, University of Southern California, USC.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.